Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

被引：0
作者：
I Bernard Weinstein
Andrew K Joe
机构：
[1] Frode Jensen Professor of Medicine,
[2] Genetics and Development,undefined
[3] and Public Health at the College of Physicians and Surgeons,undefined
[4] Columbia University,undefined
[5] Florence Irving Assistant Professor of Clinical Medicine,undefined
[6] College of Physicians and Surgeons,undefined
[7] Columbia University,undefined
来源：
Nature Clinical Practice Oncology | 2006年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The oncogene addition concept was established to explain how some cancers that contain multiple genetic, epigenetic, and chromosomal abnormalities are dependent on or are “addicted” to one or more genes for both maintenance of the malignant phenotype and cell survival. Weinstein and Joe summarize current experimental and clinical evidence of this concept and describe some of the molecular mechanisms of this phenomenon. The use of molecular targeted agents in combination with cytotoxic agents, and the advances in systems biology and network theory can help to facilitate an optimal treatment approach.
引用
收藏
页码：448 / 457
页数：9
相关论文
共 84 条
  • [41] Baselga J(2005)Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck J Clin Oncol 23 792-799
  • [42] Cunningham D(2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 350 2335-2342
  • [43] Miller KD(2003)Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer N Engl J Med 349 427-434
  • [44] Hurwitz H(2001)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer Science 293 876-880
  • [45] Yang JC(2005)A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 352 786-792
  • [46] Gorre ME(2002)Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Cancer Res 62 7149-7153
  • [47] Kobayashi S(1994)EGFR mutation and resistance of non-small-cell lung cancer to gefitinib Cancer 73 2013-2026
  • [48] La Rosee P(2001)Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec Proc Natl Acad Sci USA 98 10031-10033
  • [49] Kerr JF(2004), STI571) Science 305 1163-1167
  • [50] Mills GB(2005)Apoptosis. Its significance in cancer and cancer therapy J Natl Cancer Inst 97 643-655
123456789